AllergyTalk Episode 12: Changing Biologics, Mucus Viscosity, Pemphigus and Food Allergy
Price: FREE for members and non-members
Viewers can earn credit by listening to the podcast and completing the post test questions.
AllergyTalk is a podcast designed to provide easy access to research summaries from AllergyWatch and recommendations from subject matter experts in order to bring physicians up to date in the latest advances in the field of allergy and immunology.
There is no commercial support for this activity.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Primary Care Providers
Fellows-in-Training
Learning Objectives
Upon completion of this activity learners should be able to:
- Recognize the response to alternative biologics in patients with severe eosinophilic asthma not controlled with omalizumab.
- State the physical properties of nasal secretions in patients with post-nasal drainage.
- Recognize allergens as a possible trigger for pemphigus vulgaris.
All identified conflicts of interest have been resolved.
Stanley Fineman, MD
Disclosures: Independent contractor/contracted research: Aimmune, DVB Technologies, BioCryst, Regeneron; Speaker/honorarium: Boehringer-Ingelheim, Takeda/Shire
Merin Kalangara (Kuruvilla), MD
Nothing to disclose
Gerald Lee, MD
Nothing to disclose
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance